Mordant P, Pricopi C, Legras A, Arame A, Foucault C, Dujon A, Le Pimpec-Barthes F, Riquet M
Department of General Thoracic Surgery, Georges Pompidou European Hospital, Descartes University, Paris, France.
Cedar Surgical Centre, Bois Guillaume, France.
Eur J Surg Oncol. 2015 May;41(5):696-701. doi: 10.1016/j.ejso.2014.10.003. Epub 2014 Oct 15.
Non-small cell lung carcinoma (NSCLC) with N1 involvement is associated with 5-year survival rates ranging from 7% to 55%. Numerous factors have been independently reported to explain this heterogeneous prognosis, but their relative weight on long-term survival is unknown.
Patients who underwent surgical resection for NSCLC in two French centers from 1993 to 2010 were prospectively recorded and retrospectively reviewed. The overall survival (OS) of patients undergoing first-line surgery for pN1 disease was analyzed according to the type of extension, number of metastatic LN, number and anatomic location of metastatic stations.
The study group included 450 patients (male 80.2%, mean age 63.3 ± 9.9 years, 5-year overall survival 46%). The number of metastatic station was 1 in 340 (75.6%, single-station disease) and ≥2 in 110 patients (24.4%, multi-station disease). The number of metastatic stations was correlated with the number of metastatic LN (p < .001), and associated with adverse OS (p = .0014). The presence of intralobar metastatic LN (station 12-13-14) was associated with a mechanism of direct extension (p < .001), but did not impact OS (p = .71). The location of metastatic stations was of prognostic significance only in case of multi-station disease, with hilar (station 10) involvement being associated with adverse OS (p = .005). The 110 patients with multi-station pN1 disease and the 134 patients operated on for single-station pN0N2 (skip-N2) disease during the study period yield comparable outcome (p = .52).
In patients with resected pN1 NSCLC, the number of metastatic stations and their location in case of multi-station disease have a prognostic value.
N1期非小细胞肺癌(NSCLC)患者的5年生存率在7%至55%之间。众多因素已被独立报道可解释这种预后异质性,但它们对长期生存的相对影响尚不清楚。
前瞻性记录并回顾性分析了1993年至2010年在法国两个中心接受NSCLC手术切除的患者。根据转移范围类型、转移淋巴结数量、转移站数量及解剖位置,分析了pN1期疾病接受一线手术患者的总生存期(OS)。
研究组包括450例患者(男性占80.2%,平均年龄63.3±9.9岁,5年总生存率46%)。340例患者转移站数量为1个(75.6%,单站疾病),110例患者转移站数量≥2个(24.4%,多站疾病)。转移站数量与转移淋巴结数量相关(p<0.001),且与不良OS相关(p=0.0014)。叶内转移淋巴结(12-13-14站)的存在与直接蔓延机制相关(p<0.001),但不影响OS(p=0.71)。转移站位置仅在多站疾病情况下具有预后意义,肺门(10站)受累与不良OS相关(p=0.005)。研究期间,110例多站pN1期疾病患者和134例接受单站pN0N2(跳跃N2)疾病手术的患者预后相当(p=0.52)。
在接受手术切除的pN1期NSCLC患者中,转移站数量及其在多站疾病情况下的位置具有预后价值。